BBLG (Bone Biologics) EPS (Basic) : $-7.25 (TTM As of Sep. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Bone Biologics EPS (Basic)?

Bone Biologics's basic earnings per share (Basic EPS) for the three months ended in Sep. 2024 was $-2.37. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2024 was $-7.25.

Bone Biologics's EPS (Diluted) for the three months ended in Sep. 2024 was $-2.37. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-7.25.

Bone Biologics's EPS without NRI for the three months ended in Sep. 2024 was $-2.36. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2024 was -6.58.

During the past 3 years, the average EPS without NRI Growth Rate was 38.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was 38.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 10 years, Bone Biologics's highest 3-Year average EPS without NRI Growth Rate was 57.50% per year. The lowest was -9.60% per year. And the median was 40.70% per year.

Bone Biologics EPS (Basic) Historical Data

The historical data trend for Bone Biologics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bone Biologics EPS (Basic) Chart

Bone Biologics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

-282.00

-151.20

-84.00

-31.15

-34.01

Bone Biologics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EPS (Basic)	Get a 7-Day Free Trial															-4.90	-2.90	-1.31	-0.67	-2.37

Bone Biologics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Bone Biologics's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-8.949	-	0)	/	0.263
	=	-34.03

Bone Biologics's Basic EPS for the quarter that ended in Sep. 2024 is calculated as

Basic EPS (Q: Sep. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-0.941	-	0)	/	1.753
	=	-0.54

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.25

Bone Biologics (NAS:BBLG) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Bone Biologics EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Bone Biologics's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Bone Biologics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bone Biologics Corp (NAS:BBLG) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

2 Burlington Woods Drive, Suite 100, Burlington, MA, USA, 01803

Website

https://www.bonebiologics.com

Bone Biologics Corp is a healthcare solutions provider based in the United States. As a biotechnology firm, it engages its efforts in developing therapeutics to aid bone regeneration. The company's portfolio comprises its lead product, NELL-1, which is a bone void filler. Bone Biologics' technology has applications in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.

Executives

Deina H Walsh	officer: Chief Financial Officer	175, MAY STREET, EDISON NJ 08837
Jeff Frelick	officer: Chief Operating Officer	1 FOX RUN LANE,, LEXINGTON MA 02420
Knight Insurance Company, Ltd	10 percent owner	4751 WILSHIRE BLVD.,, SUITE 111, LOS ANGELES CA 90010
Siddhesh Rajendra Angle	director	481 MONMOUTH ST, UNIT G,, JERSEY CITY NJ 07302
Erick Lucera	director	138 THISTLE ROAD, NORTH ANDOVER MA 08145
Don Hankey	director, 10 percent owner, officer: Chairman of the Board	4751 WILSHIRE BLVD., SUITE 110, LOS ANGELES CA 90010
Bret Hankey	director	4751 WILSHIRE BLVD. #110, LOS ANGELES CA 90010
Hankey Capital, Llc	10 percent owner	4751 WILSHIRE BLVD., #110, LOS ANGELES CA 90010
Don Hankey Trust	10 percent owner	4751 WILSHIRE BLVD., #110, LOS ANGELES CA 90010
Amir F Heshmatpour	10 percent owner	269 S. BEVERLY DRIVE, STE #1600, BEVERLY HILLS CA 90212
Musculoskeletal Transplant Foundation, Inc.	director	175 MAY STREET, SUITE 300, EDISON NJ 08837
Benjamin Wu	director	2740 LORAIN ROAD, SAN MARINO CA 91108
La Neve Stephen R.	director, officer: CEO and President	106 MCCOOL BLVD, WEST CHESTER PA 19380
George A Oram	director	12 EDGEMONT LANE, BEDMINSTER NJ 07921
Jim Delshad	director	132 S. MAPLE DR., BEVERLY HILLS CA 90212